2026 Q2 Portfolio Activity
In 2026 Q2, DAFNA Capital Management LLC maintained a portfolio of 100 distinct positions. The most significant new addition was KYMERA THERAPEUTICS INC, now representing 0.59% of the total fund value. They heavily accumulated shares in DENALI THERAPEUTICS INC, increasing the position by 132.0%. Conversely, DAFNA Capital Management LLC completely exited their position in DAY ONE BIOPHARMACEUTICALS I.
Position History
hover any row below to update
Loading…
Total Positions
100
Quarter
2026 Q2
Top Holding
RVMD (20.1%)
Top 10 Concentration
56.2%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 100
DAFNA Capital Management LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 20.09% | 12.85% |
#1
Prev: #1
|
6.5 |
—
|
-18,048 | -3.1% |
P
S
|
562,630 | $105,369,346 | 2020 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XBI
SPDR S&P BIOTEC...
|
ETF | 5.93% | 9.25% |
#2
Prev: #2
|
3.9 |
—
|
-122,000 | -38.3% |
P
S
|
196,505 | $31,096,916 | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CMPS
COMPASS PATHWAY...
|
Healthcare | 5.43% | 3.04% |
#3
6
Prev: #9
|
3.7 |
—
|
-406,930 | -16.8% |
P
S
|
2,011,952 | $28,469,121 | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
STXS
STEREOTAXIS INC
|
Healthcare | 4.49% | 5.73% |
#4
1
Prev: #3
|
3.3 |
—
|
no change | no change |
P
S
|
13,680,554 | $23,530,553 | 2012 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 4.24% | 2.70% |
#5
5
Prev: #10
|
5.2 |
—
|
153,202 | 92.7% |
P
S
|
318,380 | $22,226,108 | 2009 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DNLI
DENALI THERAPEU...
|
Healthcare | 3.62% | 1.39% |
#6
13
Prev: #19
|
4.4 |
—
|
420,514 | 132.0% |
P
S
|
739,014 | $19,007,440 | 2025 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 3.53% | 3.61% |
#7
1
Prev: #6
|
1.9 |
—
|
20,500 | 4.3% |
P
S
|
497,240 | $18,532,135 | 2020 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ATRC
ATRICURE INC
|
Healthcare | 3.19% | 3.88% |
#8
3
Prev: #5
|
2.3 |
—
|
no change | no change |
P
S
|
597,431 | $16,716,119 | 2012 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.89% | 3.32% |
#9
2
Prev: #7
|
2.2 |
—
|
no change | no change |
P
S
|
250,772 | $15,136,598 | 2015 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 2.79% | 3.26% |
#10
2
Prev: #8
|
1.1 |
—
|
-45,499 | -20.9% |
P
S
|
171,998 | $14,652,510 | 2015 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RCUS
ARCUS BIOSCIENC...
|
Healthcare | 2.60% | 2.18% |
#11
1
Prev: #12
|
1.5 |
—
|
-2,000 | -0.5% |
P
S
|
441,829 | $13,621,588 | 2018 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
ASCENDIS PHARMA...
|
|
Unknown | 2.47% | — |
#12
Prev: #—
|
4.5 |
—
|
48,469 | — |
NEW
|
48,469 | $12,927,652 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
NBIX
NEUROCRINE BIOS...
|
Healthcare | 1.86% | 2.12% |
#13
Prev: #13
|
1.2 |
—
|
-12,846 | -18.2% |
P
S
|
57,769 | $9,736,098 | 2008 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AXGN
AXOGEN INC
|
Healthcare | 1.84% | 1.88% |
#14
2
Prev: #16
|
1.2 |
—
|
-41,000 | -16.4% |
P
S
|
208,960 | $9,651,862 | 2021 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PODD
INSULET CORP
|
Healthcare | 1.80% | 0.52% |
#15
26
Prev: #41
|
3.7 |
—
|
51,000 | 469.2% |
P
S
|
61,870 | $9,419,708 | 2008 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 1.76% | 0.80% |
#16
17
Prev: #33
|
3.7 |
—
|
114,583 | 102.1% |
P
S
|
226,819 | $9,215,656 | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCAX
BICARA THERAPEU...
|
Healthcare | 1.61% | 1.91% |
#17
2
Prev: #15
|
0.6 |
—
|
-136,778 | -32.4% |
P
S
|
284,955 | $8,460,314 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IBB
ISHARES NASDAQ ...
|
ETF | 1.54% | 2.39% |
#18
7
Prev: #11
|
0.6 |
—
|
-19,500 | -31.4% |
P
S
|
42,595 | $8,101,143 | 2006 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 1.40% | 1.16% |
#19
8
Prev: #27
|
3.6 |
—
|
117,900 | 54.2% |
P
S
|
335,255 | $7,328,674 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MPLT
MAPLIGHT THERAP...
|
Healthcare | 1.17% | 0.79% |
#20
14
Prev: #34
|
1.5 |
—
|
no change | no change |
P
S
|
171,006 | $6,128,855 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LRMR
LARIMAR THERAPE...
|
Healthcare | 1.17% | 2.08% |
#21
7
Prev: #14
|
1.0 |
—
|
-21,000 | -1.0% |
P
S
|
2,008,164 | $6,124,900 | 2020 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IPSC
CENTURY THERAPE...
|
Healthcare | 1.12% | 1.25% |
#22
1
Prev: #21
|
0.9 |
—
|
-33,895 | -1.4% |
P
S
|
2,400,458 | $5,881,122 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
DXCM
DEXCOM INC
|
Healthcare | 1.11% | 1.23% |
#23
1
Prev: #22
|
1.4 |
—
|
no change | no change |
P
S
|
86,279 | $5,810,891 | 2012 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 1.10% | 0.85% |
#24
8
Prev: #32
|
0.9 |
—
|
-1,000 | -0.7% |
P
S
|
149,524 | $5,761,160 | 2023 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
INGN
INOGEN INC
|
Healthcare | 1.04% | 1.19% |
#25
1
Prev: #26
|
1.4 |
—
|
no change | no change |
P
S
|
845,179 | $5,451,405 | 2019 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
TNDM
TANDEM DIABETES...
|
Healthcare | 1.02% | 1.55% |
#26
8
Prev: #18
|
1.4 |
—
|
no change | no change |
P
S
|
355,208 | $5,360,089 | 2015 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.01% | 1.12% |
#27
1
Prev: #28
|
0.4 |
—
|
-38,216 | -27.4% |
P
S
|
101,266 | $5,305,832 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
STOK
STOKE THERAPEUT...
|
Healthcare | 0.82% | 0.97% |
#28
1
Prev: #29
|
1.3 |
—
|
no change | no change |
P
S
|
130,875 | $4,282,230 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALLO
ALLOGENE THERAP...
|
Healthcare | 0.79% | 0.76% |
#29
6
Prev: #35
|
2.8 |
—
|
629,882 | 46.0% |
P
S
|
2,000,000 | $4,160,000 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 0.76% | 0.93% |
#30
Prev: #30
|
0.8 |
—
|
-30,000 | -7.0% |
P
S
|
400,248 | $4,002,480 | 2014 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLPG
LAKEFRONT BIOTH...
|
Healthcare | 0.74% | 0.89% |
#31
Prev: #31
|
1.3 |
—
|
no change | no change |
P
S
|
130,175 | $3,902,647 | 2015 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KIDS
ORTHOPEDIATRICS...
|
Healthcare | 0.69% | 0.35% |
#32
21
Prev: #53
|
3.3 |
—
|
93,471 | 97.7% |
P
S
|
189,130 | $3,618,057 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CYBN
CYBIN INC
|
Unknown | 0.65% | 0.54% |
#33
6
Prev: #39
|
0.8 |
—
|
15,700 | 3.2% |
P
S
|
514,061 | $3,397,943 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
RAPP
RAPPORT THERAPE...
|
Healthcare | 0.60% | 0.53% |
#34
6
Prev: #40
|
1.2 |
—
|
no change | no change |
P
S
|
75,000 | $3,125,250 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KYMR
KYMERA THERAPEU...
|
Healthcare | 0.59% | — |
#35
Prev: #—
|
3.7 |
—
|
27,000 | — |
NEW
|
27,000 | $3,096,090 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PRQR
PROQR THERAPEUT...
|
Healthcare | 0.54% | 0.58% |
#36
2
Prev: #38
|
0.7 |
—
|
-37,200 | -2.4% |
P
S
|
1,530,361 | $2,846,471 | 2017 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NGNE
NEUROGENE INC
|
Healthcare | 0.53% | 0.26% |
#37
19
Prev: #56
|
3.2 |
—
|
32,397 | 57.2% |
P
S
|
89,032 | $2,800,056 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ANL
ADLAI NORTYE LT...
|
Healthcare | 0.53% | — |
#38
Prev: #—
|
3.7 |
—
|
239,553 | — |
NEW
|
239,553 | $2,754,860 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PRCT
PROCEPT BIOROBO...
|
Healthcare | 0.52% | 0.68% |
#39
3
Prev: #36
|
1.2 |
—
|
no change | no change |
P
S
|
120,000 | $2,709,600 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AQST
AQUESTIVE THERA...
|
Healthcare | 0.51% | 0.35% |
#40
11
Prev: #51
|
3.2 |
—
|
277,500 | 75.3% |
P
S
|
645,915 | $2,687,006 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 0.49% | 0.49% |
#41
3
Prev: #44
|
1.2 |
—
|
no change | no change |
P
S
|
68,518 | $2,549,555 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 0.48% | 0.51% |
#42
Prev: #42
|
1.2 |
—
|
no change | no change |
P
S
|
46,500 | $2,495,655 | 2024 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALGN
ALIGN TECHNOLOG...
|
Healthcare | 0.45% | 0.58% |
#43
6
Prev: #37
|
0.7 |
—
|
-1,000 | -6.7% |
P
S
|
14,000 | $2,361,240 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VKTX
VIKING THERAPEU...
|
Healthcare | 0.44% | 0.44% |
#44
3
Prev: #47
|
1.2 |
—
|
no change | no change |
P
S
|
59,516 | $2,321,719 | 2018 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NGENF
NERVGEN PHARMA ...
|
Unknown | 0.41% | — |
#45
Prev: #—
|
3.7 |
—
|
1,050,000 | — |
NEW
|
1,050,000 | $2,163,000 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BHVN
BIOHAVEN LTD
|
Healthcare | 0.39% | 1.63% |
#46
29
Prev: #17
|
0.2 |
—
|
-708,142 | -83.7% |
P
S
|
137,593 | $2,047,384 | 2018 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.37% | 0.24% |
#47
12
Prev: #59
|
3.1 |
—
|
30,000 | 85.7% |
P
S
|
65,000 | $1,939,600 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALEC
ALECTOR INC
|
Healthcare | 0.35% | 0.44% |
#48
2
Prev: #46
|
1.1 |
—
|
no change | no change |
P
S
|
908,351 | $1,825,786 | 2019 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 0.33% | 0.49% |
#49
4
Prev: #45
|
1.1 |
—
|
no change | no change |
P
S
|
377,059 | $1,755,210 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PROF
PROFOUND MEDICA...
|
Healthcare | 0.33% | 0.39% |
#50
1
Prev: #49
|
0.6 |
—
|
-2,645 | -1.0% |
P
S
|
260,360 | $1,731,394 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-50 of 100 holdings